TRxADE Group Reports Annual Revenue Growth of 130% and Year End 2020 Financial Results
Trxade Group, Inc. (NASDAQ: MEDS) reported strong financial results for Q4 and FY 2020. Revenues for Q4 2020 increased by 17.1% to $2 million, while full-year revenues surged 130.3% to $17.1 million, driven by Trxade Platform and PPE sales. However, gross profit declined 90% in Q4, with a net loss of $2.3 million. The company expanded its drug procurement marketplace, added over 328 new members, and launched the MedCheks subsidiary for a Digital Health Passport. Operating expenses rose significantly due to goodwill impairment and increased staff for B2C expansion.
- Revenues increased 130.3% for FY 2020 to $17.1 million.
- Added 328 new registered members in Q4, totaling approximately 11,800+.
- Launched new subsidiary MedCheks to develop a Digital Health Passport.
- Gross profit dropped 90% in Q4 2020 to $0.1 million.
- Net loss for Q4 2020 increased to $2.3 million, compared to $0.5 million in Q4 2019.
- Operating expenses rose significantly to $2.4 million in Q4 due to goodwill impairment.
Continues Nationwide Expansion of Breakthrough Digital Healthcare Services IT Platform
TAMPA, FL, March 29, 2021 (GLOBE NEWSWIRE) -- Trxade Group, Inc. (NASDAQ: MEDS), a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S., today announced its financial results for the fourth quarter (Q4) and year ended (FY) December 31, 2020.
Selected Financial Highlights
| $ in Millions | Q4 | % Increase (Decrease) | FY | % Increase (Decrease) | ||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||
| Revenues | 17.1 | % | 130.3 | % | ||||||||
| Gross Profit | (90.0 | %) | 17.2 | % | ||||||||
| Gross Margin Percentage | 6.5 | % | 76.5 | % | (91.5 | %) | 33.3 | % | 65.5 | % | (49.1 | %) |
| Net Loss | ( | ) | ( | ) | (362.0 | %) | ( | ) | ( | ) | (791.6 | %) |
| Adjusted EBITDA* | ( | ) | (929.4 | %) | (89.7 | %) | ||||||
*Adjusted EBITDA is a non-GAAP financial measure and is described in relation to its most directly comparable GAAP measure under “Use of Non-GAAP Financial Information” below.
Fourth Quarter 2020 and Subsequent Operational Highlights
- Trxade continued to expand the Trxade drug procurement marketplace nationwide, adding 328 new registered members in Q4 2020, bringing the total registered members to approximately 11,800+.
- Appointed technology entrepreneur and industry thought leader James Ram, to lead the company's newly launched MedCheks subsidiary, in its efforts to bring a Digital Health Passport to market, allowing the holder to display vaccination and COVID-19 testing status.
- Trxade’s telehealth subsidiary Bonum Health signed a strategic partnership to provide affordable telemedicine services to the patients of approximately 100 Kinney Drug retail pharmacies in New York and Vermont, and, the more than two million Rx discount card members of Kinney's sister company, ProAct, Inc., a fully integrated pharmacy benefits manager.
- Launched Trxade Prime, a revolutionary service offered by the Company’s wholesale division, allowing the registered members on the Trxade platform to process, consolidate and ship orders that are placed directly with Trxade Suppliers.
- Announced partnership with SingleCare, a free prescription savings service, to supplement Bonum Health’s enterprise telehealth solutions with prescription discounts offered to national, regional and local pharmacies to promote the benefit to uninsured patients and underserved communities.
Management Commentary
“2020 was a milestone year for our company as we continued to innovate, grow and expand. Despite the challenges of a global pandemic, we increased revenues by
“I am particularly pleased to announce the launch of our new subsidiary, MedCheks, which is developing a digital health passport to help facilitate the safe reopening of the global economy. To head this new initiative, we brought on James Ram. Under his lead, the Digital Health Passport is planned to leverage both state-of-the-art encryption and blockchain technology to conceal all private health data, allowing for the secure exchange of data between passport holder and verifier. We are evaluating initial roll-out locations for the pay-per-use model.
“Bonum Health, our telehealth subsidiary, made significant strides in the fourth quarter to more rapidly propel adoption nationwide. We signed an exciting partnership with KPH Healthcare services, bringing affordable healthcare to the patients of approximately 100 Kinney Drug retail pharmacies on the East Coast.
“Throughout the year, we have continued to drive our business forward, achieving several key milestones in our internal roadmap with a focus on innovation and development through our various complementary growth opportunities. This is an exciting time for Trxade, and I believe we are better positioned to create sustainable value for our shareholders than at any prior time in the Company's history,” concluded Mr. Ajjarapu, the Company’s Chairman and Chief Executive Officer.
Fourth Quarter 2020 Financial Summary
- Revenues for the fourth quarter of 2020, increased
17.1% to$2 million , compared to revenue of$1.7 million in the same quarter last year. The increase in revenue was primarily due to revenue generated by the Trxade Platform and Trxade Prime. - Gross profit in the fourth quarter of 2020, decreased
90.0% to$0.1 million , or6.5% of revenues, compared to gross profit of$1.3 million , or76.5% of revenues, in the same quarter last year. The decrease in gross profit was primarily attributable to higher costs associated with Trxade Prime transactions and a write down of inventory. - Operating expenses in the fourth quarter of 2020 were
$2.4 million , compared to$1.6 million in the same quarter last year. This increase is primarily due to the Loss on Impairment of Goodwill of$726,000 and an increase in employees with our expansion into Business to Consumer (B2C) sales. - Net loss in the fourth quarter of 2020 was
$2.3 million , or$0.29 per basic and diluted share outstanding, as a result of the Loss on Impairment of Goodwill and a$1,081,000 inventory write down, compared to a net loss of$0.5 million , or$0.04 per basic and diluted share outstanding, in the same quarter last year. - Adjusted EBITDA, a non-GAAP financial measure, decreased to (
$1.4) million for the fourth quarter of 2020, compared to$0.2 million in the same quarter last year.
Fiscal Year Ended December 31, 2020 Summary
- Revenues for the year ended December 31, 2020, increased
130.3% to$17.1 million , compared to revenue of$7.4 million in the previous year. The increase in revenue was due to revenue generated by Trxade Platform, Trxade Prime and Integra Pharma Solutions, our wholly-owned subsidiary, which revenue increase mainly related to Personal Protective Equipment (PPE) sales relating to the COVID-19 pandemic. - Gross profit for 2020 increased
17.2% to$5.7 million , or33.3% of revenues, compared to gross profit of$4.8 million , or65.5% of revenues, in the same period last year. The increase in gross profit was attributable to higher costs associated with Trxade Prime and Integra Pharma transactions. - Operating expenses for the full year 2020 were
$8.2 million , compared to$4.7 million in the last year. This increase is due to the Loss on Impairment of Goodwill, an increase in employees with our expansion into Business to Consumer (B2C) sales, IT initiatives, and non-cash compensation. - Net loss for the year ended December 31, 2020, was (
$2.5) million , or ($0.33) per basic and diluted share outstanding, compared to net loss of ($0.3) million , or ($0.05) per basic and diluted share outstanding, in the last year. - Adjusted EBITDA, a non-GAAP financial measure, was
$0.1 million , compared to$0.85 million for the year ended 2020 and 2019, respectively. - Cash and cash equivalents were
$5.9 million as of December 31, 2020, compared with$2.9 million as of December 31, 2019.
Conference Call and Webcast
Management will host a conference call on Monday, March 29, 2021 at 5:00 p.m. Eastern time to discuss Trxade Group’s fourth quarter and fiscal year 2020 financial results. The call will conclude with Q&A from participants. To participate, please use the following information:
Q4 and Fiscal Year 2020 Conference Call and Webcast
Date: Monday, March 29, 2021
Time: 5:00 p.m. Eastern time
U.S. Dial-in: 1-877-425-9470
International Dial-in: 1-201-389-0878
Conference ID: 13716956
Webcast: http://public.viavid.com/index.php?id=143721
Please dial in at least 10 minutes before the start of the call to ensure timely participation.
A playback of the call will be available through April 29, 2021. To listen, call 1-844-512-2921 within the United States or 1-412-317-6671 when calling internationally and enter replay pin number 13716956. A webcast will also be available for 30 days on the IR section of the Trxade Group website or by clicking the webcast link above.
About Trxade Group, Inc.
Trxade Group (NASDAQ: MEDS) is a health services IT company focused on digitalizing the retail pharmacy experience by optimizing drug procurement, the prescription journey and patient engagement in the U.S. The Company operates the TRxADE drug procurement marketplace serving a total of 11,800+ members nationwide, fostering price transparency and under the Bonum Health brand, offering patient centric telehealth services. For more information on Trxade Group, please visit the Company’s IR website at investors.trxadegroup.com.
Use of Non-GAAP Financial Information
This earnings release discusses EBITDA and Adjusted EBITDA. These measurements are not recognized in accordance with generally accepted accounting principles (GAAP) and should not be viewed as an alternative to GAAP measures of performance. EBITDA represents net income before interest, taxes, depreciation and amortization. Adjusted EBITDA is defined as EBITDA before stock-based compensation expense and gain (loss) in equity investment. EBITDA and Adjusted EBITDA are presented because we believe they provide additional useful information to investors due to the various noncash items during the period. EBITDA and Adjusted EBITDA have limitations as analytical tools, and you should not consider them in isolation, or as a substitute for analysis of our operating results as reported under GAAP. Some of these limitations are: EBITDA and Adjusted EBITDA do not reflect cash expenditures, future requirements for capital expenditures, or contractual commitments; EBITDA and Adjusted EBITDA do not reflect changes in, or cash requirements for, working capital needs; and EBITDA and Adjusted EBITDA do not reflect the significant interest expense, or the cash requirements necessary to service interest or principal payments, on debt or cash income tax payments. Although depreciation and amortization are noncash charges, the assets being depreciated and amortized will often have to be replaced in the future, and EBITDA and Adjusted EBITDA do not reflect any cash requirements for such replacements. Additionally, other companies in our industry may calculate EBITDA and Adjusted EBITDA differently than Trxade Group, Inc. does, limiting its usefulness as a comparative measure. See also “Reconciliation of Net Income attributable to Trxade Group, Inc., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA”, below.
Forward-Looking Statements
This press release may contain forward-looking statements, including information about management’s view of Trxade’s future expectations, plans and prospects, within the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 (the “Act”). In particular, when used in the preceding discussion, the words “may,” “could,” “expect,” “intend,” “plan,” “seek,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “likely,” “will,” “would” and variations of these terms and similar expressions, or the negative of these terms or similar expressions are intended to identify forward-looking statements within the meaning of the Act, and are subject to the safe harbor created by the Act. Any statements made in this news release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of Trxade, its divisions and concepts to be materially different than those expressed or implied in such statements. These risks include risks of our operations not being profitable; claims relating to alleged violations of intellectual property rights of others; technical problems with our websites; risks relating to implementing our acquisition strategies; our ability to manage our growth; negative effects on our operations associated with the opioid pain medication health crisis; regulatory and licensing requirement risks; risks related to changes in the U.S. healthcare environment; the status of our information systems, facilities and distribution networks; risks associated with the operations of our more established competitors; regulatory changes; healthcare fraud; COVID-19, governmental responses thereto, economic downturns and possible recessions caused thereby; changes in laws or regulations relating to our operations; privacy laws; system errors; dependence on current management; our growth strategy; and others that are included from time to time in filings made by Trxade with the Securities and Exchange Commission, including, but not limited to, in the “Risk Factors” sections in its Form 10-Ks and Form 10-Qs and in its Form 8-Ks, which it has filed, and files from time to time, with the U.S. Securities and Exchange Commission. These reports are available at www.sec.gov. Other unknown or unpredictable factors also could have material adverse effects on Trxade’s future results and/or could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements. The forward-looking statements included in this press release are made only as of the date hereof. Trxade cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. We undertake no obligation to update publicly any of these forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable laws. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.
Investor Relations:
Lucas Zimmerman
Senior Vice President
MZ Group - MZ North America
(949) 259-4987
MEDS@mzgroup.us
www.mzgroup.us
Trxade Group, Inc.
Consolidated Balance Sheets
December 31, 2020 and 2019
| December 31, 2020 | December 31, 2019 | |||||||
| Assets | ||||||||
| Current Assets | ||||||||
| Cash | $ | 5,919,578 | $ | 2,871,694 | ||||
| Accounts Receivable, net | 805,043 | 792,050 | ||||||
| Inventory | 1,257,754 | 56,761 | ||||||
| Prepaid Assets | 151,248 | 82,452 | ||||||
| Other Receivables | 1,087,675 | - | ||||||
| Total Current Assets | 9,221,298 | 3,802,957 | ||||||
| Property Plant and Equipment, Net | 162,397 | 174,987 | ||||||
| Other Assets | ||||||||
| Deposits | 21,636 | 21,636 | ||||||
| Deferred offering costs | - | 88,231 | ||||||
| Right of use leased assets | 387,371 | 757,710 | ||||||
| Goodwill | - | 725,973 | ||||||
| Total Assets | $ | 9,792,702 | $ | 5,571,494 | ||||
| Liabilities and Stockholders’ Equity | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $ | 256,829 | $ | 334,614 | ||||
| Accrued Liabilities | 219,256 | 98,852 | ||||||
| Current Portion – Operating Lease Liabilities | 131,153 | 87,350 | ||||||
| Customer Deposits | 10,000 | - | ||||||
| Notes Payable – Related Party | 225,000 | - | ||||||
| Total Current Liabilities | 842,238 | 520,816 | ||||||
| Long Term Liabilities | ||||||||
| Notes Payable – Related Party | - | 225,000 | ||||||
| Operating Lease Liabilities, net of current portion | 271,306 | 685,461 | ||||||
| Total Liabilities | 1,113,544 | 1,431,277 | ||||||
| Stockholders’ Equity | ||||||||
| Series A Preferred Stock, | - | - | ||||||
| Common Stock, | 81 | 65 | ||||||
| Additional Paid-in Capital | 19,610,631 | 12,535,655 | ||||||
| Retained Deficit | (10,931,554 | ) | (8,395,503 | ) | ||||
| Total Stockholders’ Equity | 8,679,158 | 4,140,217 | ||||||
| Total Liabilities and Stockholders’ Equity | $ | 9,792,702 | $ | 5,571,494 | ||||
Trxade Group, Inc.
Consolidated Statements of Operations
Years Ended December 31, 2020 and 2019
| 2020 | 2019 | |||||||
| Revenues, net | $ | 17,122,520 | $ | 7,436,264 | ||||
| Cost of Sales | 11,415,198 | 2,565,500 | ||||||
| Gross Profit | 5,707,322 | 4,870,764 | ||||||
| Operating Expenses | ||||||||
| Loss on write-off of software asset | - | 368,520 | ||||||
| Loss on Impairment of Goodwill | 725,973 | - | ||||||
| General and Administrative | 7,488,011 | 4,377,020 | ||||||
| Total Operating Expenses | 8,213,984 | 4,745,540 | ||||||
| Operating Income (Loss) | (2,506,662 | ) | 125,224 | |||||
| Other Income | - | 72,075 | ||||||
| Investment Loss | - | (250,000 | ) | |||||
| Loss on Extinguishment of Debt | - | (178,500 | ) | |||||
| Interest Expense | (29,389 | ) | (53,227 | ) | ||||
| Net Loss | $ | (2,536,051 | ) | $ | (284,428 | ) | ||
| Net Loss per Common Share – Basic and Diluted | $ | (0.33 | ) | $ | (0.05 | ) | ||
| Weighted average Common Shares Outstanding Basic and Diluted | 7,705,620 | 5,929,092 | ||||||
Trxade Group, Inc.
Consolidated Statements of Cash Flows
Years ended December 31, 2020 and 2019
| 2020 | 2019 | |||||||
| Operating Activities: | ||||||||
| Net loss | $ | (2,536,051 | ) | $ | (284,428 | ) | ||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
| Depreciation Expense | 5,500 | 5,000 | ||||||
| Options Expense | 448,404 | 176,376 | ||||||
| Warrant Expense | 56,885 | 105,452 | ||||||
| Common Stock Issued for Services | 1,357,759 | - | ||||||
| Bad Debt Expense | 10,539 | 11,500 | ||||||
| Loss on extinguishment of debt | - | 178,500 | ||||||
| Investment Loss | - | 250,000 | ||||||
| Loss on write off of software asset | - | 277,500 | ||||||
| Loss on Impairment of Goodwill | 725,973 | - | ||||||
| Loss on write-down of Inventory | 1,218,020 | - | ||||||
| Amortization of Right-of-Use Asset | 97,020 | 89,731 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Accounts Receivable | (23,532 | ) | (369,923 | ) | ||||
| Prepaid Assets and Other Current Assets | (68,796 | ) | 475 | |||||
| Other Assets | - | (89,336 | ) | |||||
| Inventory | (2,419,013 | ) | 23,205 | |||||
| Other Receivables | (1,087,675 | ) | - | |||||
| Lease Liability | (97,033 | ) | (74,630 | ) | ||||
| Accounts Payable | (33,190 | ) | (148,659 | ) | ||||
| Accrued Liabilities and Other Liabilities | 120,404 | (8,988 | ) | |||||
| Customer Deposits | 10,000 | - | ||||||
| Net Cash provided by (used in) operating activities | (2,214,786 | ) | 141,775 | |||||
| Investing Activities: | ||||||||
| Purchase of Fixed Assets | (37,505 | ) | (82,252 | ) | ||||
| Purchase of Equity Method Investment | - | (250,000 | ) | |||||
| Net Cash Used in Investing Activities | (37,505 | ) | (332,252 | ) | ||||
| Financing Activities: | ||||||||
| Repayments of Short-Term Convertible Debt – Related Parties | - | (262,552 | ) | |||||
| Payment of Stock Issuance Costs | (732,356 | ) | - | |||||
| Proceeds from Exercise of Warrants | 37,606 | 166 | ||||||
| Proceeds from Exercise of Stock Options | 501 | - | ||||||
| Proceeds from Issuance of Common Stock | 5,994,424 | 2,455,000 | ||||||
| Net Cash provided by financing activities | 5,300,175 | 2,192,614 | ||||||
| Net increase in Cash | 3,047,884 | 2,002,137 | ||||||
| Cash at Beginning of the Year | 2,871,694 | 869,557 | ||||||
| Cash at End of the Year | $ | 5,919,578 | $ | 2,871,694 | ||||
| Supplemental Cash Flow Information | ||||||||
| Cash Paid for Interest | $ | 29,442 | $ | 98,461 | ||||
| Cash Paid for Income Taxes | $ | - | $ | - | ||||
| Non-Cash Transactions | ||||||||
| Recognition of ROU assets and operating lease obligations | $ | - | $ | 847,441 | ||||
| Purchase of Fixed Assets recorded in Accounts Payable | $ | - | $ | 82,729 | ||||
| Common Stock Issued for Conversion of Note and Accrued Interest | $ | - | $ | 386,983 | ||||
| Remeasurement of ROU Assets and Lease Liability for Nonrenewal of Lease | $ | 273,319 | $ | - | ||||
| Reconciliation of Net Income (Loss) attributable to Trxade Group, Inc., to Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA) and Adjusted EBITDA* | ||||||||||||||||||||
| For the three months ended December 31, | Fiscal Year ended December 31, | |||||||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||||||
| Net Income (Loss) attributable to Trxade Group, Inc. | $ | (2,312,162 | ) | $ | (495,203 | ) | $ | (2,536,051 | ) | $ | (284,428 | ) | ||||||||
| Add (deduct): | ||||||||||||||||||||
| Interest, net | 6,725 | 6,410 | 29,389 | 53,227 | ||||||||||||||||
| Depreciation and amortization | 1,750 | 1,250 | 5,500 | 5,000 | ||||||||||||||||
| EBITDA | (2,303,687 | ) | (487,543 | ) | (2,501,162 | ) | (226,201 | ) | ||||||||||||
| Add (deduct): | ||||||||||||||||||||
| Share in Equity losses on Investment | - | - | - | 250,000 | ||||||||||||||||
| Loss on write-off of software asset | - | 368,520 | - | 368,520 | ||||||||||||||||
| Loss on extinguishment of debt | - | 178,500 | - | 178,500 | ||||||||||||||||
| Loss on impairment of Goodwill | 725,973 | - | 725,973 | - | ||||||||||||||||
| Stock-based compensation | 162,877 | 113,871 | 1,863,048 | 281,828 | ||||||||||||||||
| Adjusted EBITDA * | $ | (1,414,837 | ) | $ | 178,348 | $ | 87,859 | $ | 852,647 | |||||||||||
| * EBITDA and Adjusted EBITDA are non-GAAP financial measures. These measurements are not recognized in accordance with GAAP and should not be viewed as an alternative to GAAP measures of performance. | ||||||||||||||||||||
FAQ
What were Trxade Group's revenue results for Q4 2020?
How much did Trxade Group's revenue grow for FY 2020?
What was the net loss for Trxade Group in Q4 2020?
What are the operational highlights for Trxade Group in FY 2020?
